Finoriq research workspace
Acumen Pharmaceuticals, Inc. (ABOS) SEC Filings & Filing Highlights
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted. Review ABOS SEC filings, filing highlights, and disclosure activity on Finoriq.
Company Snapshot
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers. Acumen Pharmaceuticals, Inc. has a collaboration and license agreement with Halozyme, Inc. for the development of a subcutaneous formulation of Sabirnetug, as well as with JCR Pharmaceuticals Co. Ltd for the development of Aß oligomer-targeted enhanced brain delivery therapy for the treatment of Alzheimer's disease. The company was incorporated in 1996 and is headquartered in Newton, Massachusetts.
- Company
- Acumen Pharmaceuticals, Inc. (ABOS)
- Ticker
- ABOS
- Market Cap
- $158.5M
- Latest Price
- $2.195
- Industry
- Biotech & Pharma
Acumen Pharmaceuticals, Inc. (ABOS) Recent SEC Filing Highlights
Recent SEC filings, filing events, and disclosure highlights indexed for Acumen Pharmaceuticals, Inc. (ABOS).
| Event | Form | Date |
|---|---|---|
| Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ Development Candida...Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s... | 8-K8.01 | 2026-06-16 |
| Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ Development Candida...Acumen Pharmaceuticals Announces Nomination of Two Enhanced Brain Delivery™ (EBD™) Development Candidates for the Treatment of Alzheimer’s... | 8-K7.01 | 2026-06-16 |
| Broker Non-VotesOn June 3, 2026, Acumen Pharmaceuticals, Inc. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). The stoc... | 8-K5.07 | 2026-06-03 |
| On May 12, 2026, the Company posted an updated corporate presentation to its website at https:/...On May 12, 2026, the Company posted an updated corporate presentation to its website at https://investors.acumenpharm.com/news-events/prese... | 8-K7.01 | 2026-05-12 |
| Acumen Pharmaceuticals, Inc.: Earnings or resultsOn May 12, 2026, Acumen Pharmaceuticals, Inc. (the “Company”) reported financial results and business highlights for the quarter ended Marc... | 8-K2.02 | 2026-05-12 |
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.